急诊科人群中直接口服抗凝药对血栓弹力图影响的评估
本研究为单中心回顾性队列研究,纳入40例报告使用DOAC的急诊创伤患者,其中19例使用阿哌沙班、21例使用利伐沙班,将TEG参数(R时间、K、α角、MA、LY30)与机构正常范围比较。主要结局显示仅5例(12.5%)R时间延长、1例(2.5%)MA降低,其余TEG值未提示低凝;在报告末次DOAC剂量在首选时间窗内(每日一次<12h或每日两次<6h)的患者中,仅2例(14.3%)R时间延长;在LMWH或抗Xa水平升高的亚组中,仅25%患者R时间受影响。结论提示TEG对Xa抑制剂检测不敏感,不应依赖其评估抗凝。
要点
- 急诊创伤DOAC患者40例中,仅5例(12.5%)R时间延长、1例(2.5%)MA降低,其余TEG值未提示低凝。
- 末次DOAC剂量在首选时间窗内(每日一次<12h或每日两次<6h)的患者中,仅2例(14.3%)R时间延长。
- LMWH或抗Xa水平升高的亚组中,仅25%患者R时间受影响,为唯一受影响的参数。
- 作者认为TEG对Xa抑制剂检测不敏感,不应依赖其评估此类患者的抗凝状态。
适用人群与场景
- 急诊科创伤患者,报告使用DOAC(阿哌沙班或利伐沙班)治疗。
诊断标准与关键阈值
- TEG参数正常范围采用机构参考范围;R时间、K、α角、MA、LY30为评估指标。
- 末次DOAC剂量首选时间窗:每日一次给药<12h,每日两次给药<6h。
研究设计与关键结果
- 单中心、回顾性队列研究,纳入40例报告DOAC治疗的急诊创伤患者,19例使用阿哌沙班,21例使用利伐沙班。
- 主要结局:5例(12.5%)R时间延长,1例(2.5%)MA降低,其余TEG值未提示低凝。
- 次要结局:末次DOAC剂量在首选时间窗内(每日一次<12h或每日两次<6h)的患者中,仅2例(14.3%)R时间延长。
- 亚组分析:LMWH或抗Xa水平升高的患者中,仅25%患者R时间受影响,为唯一受影响的参数。
证据类型、等级与局限
- 证据类型:单中心、回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为TEG对Xa抑制剂检测不敏感,不应依赖其评估急诊创伤患者使用利伐沙班或阿哌沙班时的抗凝状态。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Direct oral anticoagulant (DOAC) use presents a challenge to all providers involved in emergency care of patients since widely accepted laboratory tests to assess the level of anticoagulation for such medications are lacking. Viscoelastic tests such as thromboelastography (TEG) tests are increasingly used throughout major trauma centers to help guide resuscitation efforts in patients presenting with trauma and/or hemorrhagic shock.
OBJECTIVE: The primary outcome compared TEG parameters between emergency department trauma patients reporting DOAC therapy and known normal TEG parameter values. The secondary outcome evaluated patients who reported time of last known DOAC dose within a preferred time frame of <12 h for once daily dosing DOAC therapy or < 6 h for twice daily dosing DOAC therapy.
METHODS: This single-center, retrospective cohort study assessed TEG values in patients receiving DOAC therapy and compared these to institution TEG ranges considered normal. TEG values of reaction time (R time), kinetics (K), alpha angle (AA), maximum amplitude (MA), and percent lysis in 30 min (LY30) were collected for patients reporting DOAC therapy.
RESULTS: 40 patients were included in this study. 19 patients reported apixaban therapy and 21 reported rivaroxaban therapy. 5 (12.5%) patients had an elevated R time and 1 (2.5%) patient had a reduced MA. All other TEG values did not suggest hypocoagulability. For the secondary outcome assessing patients reporting last known dose within the preferred time frame, only the R time was elevated in 2 (14.3%) patients. Lastly, in a subgroup analysis of patients with elevated low-molecular-weight heparin (LMWH) orAnti- Xa levels, the R time was the only parameter affected in 25% of patients.
CONCLUSION: TEG values were typically not affected by rivaroxaban or apixaban use in an emergency department trauma population suggesting that TEG is not sensitive for Xa inhibitor detection and should not be relied upon for assessing anticoagulation in such settings.
参考来源
- Jenrette J, Schwarz K, Trujillo T, et al. Evaluation of direct oral anticoagulant use on thromboelastography in an emergency department population. Am J Emerg Med. 2021. PMID: 34952323. doi:10.1016/j.ajem.2021.12.011
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。